• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by MoonLake Immunotherapeutics

    7/3/25 1:23:21 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MLTX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001772130
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    MoonLake Immunotherapeutics
    SEC File Number
    001-39630
    Address of Issuer
    DORFSTRASSE 29
    ZUG
    SWITZERLAND
    6300
    Phone
    41 41 510 8022
    Name of Person for Whose Account the Securities are To Be Sold
    Moukheibir Catherine
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Class A
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    235001146594.656347425307/03/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Class A07/03/2025Option Granted - 04/06/2022IssuerCheckbox not checked2350007/03/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    07/03/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Catherine Moukheibir

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $MLTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLTX

    DatePrice TargetRatingAnalyst
    1/15/2026$10.00Neutral → Sell
    Goldman
    1/9/2026$24.00Neutral → Buy
    BTIG Research
    11/3/2025$30.00Neutral → Buy
    H.C. Wainwright
    10/2/2025Buy → Neutral
    H.C. Wainwright
    10/1/2025$7.00Buy → Neutral
    Goldman
    9/30/2025$2.00Outperform → Underperform
    Wolfe Research
    9/30/2025$5.00Buy → Neutral
    Citigroup
    9/29/2025$8.00Buy → Hold
    Jefferies
    More analyst ratings

    $MLTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Scientific Officer Reich Kristian

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    1/9/26 4:01:03 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Santos Da Silva Jorge

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    1/9/26 4:01:04 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Bodenstedt Matthias was granted 354,296 units of Class A ordinary shares, increasing direct ownership by 38% to 1,276,305 units (SEC Form 4)

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    1/9/26 4:01:06 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    SEC Filings

    View All

    MoonLake Immunotherapeutics filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - MoonLake Immunotherapeutics (0001821586) (Filer)

    1/8/26 8:00:54 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by MoonLake Immunotherapeutics

    SCHEDULE 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)

    11/14/25 9:03:05 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by MoonLake Immunotherapeutics

    SCHEDULE 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)

    11/10/25 5:27:37 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    MoonLake Immunotherapeutics downgraded by Goldman with a new price target

    Goldman downgraded MoonLake Immunotherapeutics from Neutral to Sell and set a new price target of $10.00

    1/15/26 8:33:55 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics upgraded by BTIG Research with a new price target

    BTIG Research upgraded MoonLake Immunotherapeutics from Neutral to Buy and set a new price target of $24.00

    1/9/26 8:33:00 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded MoonLake Immunotherapeutics from Neutral to Buy and set a new price target of $30.00

    11/3/25 9:08:28 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

    Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo

    2/10/26 7:00:00 AM ET
    $IMA
    $MLTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

    The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positive results from the Phase 2 LEDA trialThe upcoming Phase 3 program will therefore be expected to benefit from earlier and more frequent interactions with the FDA under the Fast Track program, potentially enabling a more efficient development pathway This regulatory decision follows the recent clear guidance from the FDA, in which the Company confirmed its clinical evidence strategy for the planned submission of a Biologic License Application (BLA) in H2 2026 for SLK in hidradenitis suppurativa (H

    2/2/26 8:00:00 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morning Market Pulse: From Orbit to Biomaterials, Innovation Drives the Tape

    DENVER, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Markets head into the session with a familiar but powerful theme in focus: enabling technologies that quietly unlock the next wave of growth. From satellite connectivity at cruising altitude to biologics edging closer to regulatory milestones, and from AI-driven diagnostics to advanced biomaterials, today's news flow highlights companies pushing infrastructure, science, and scale forward at the same time. Connectivity Takes Flight: flyExclusive Embraces Starlink flyExclusive (NYSE:FLYX) is setting a new benchmark in private aviation after being named an authorized Starlink Aviation dealer and installer. The move brings high-speed, low-latency sat

    1/8/26 9:32:04 AM ET
    $ACON
    $FLYX
    $MLTX
    Medical Specialities
    Health Care
    Transportation Services
    Consumer Discretionary

    $MLTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Bodenstedt Matthias bought $98,808 worth of Class A ordinary shares (10,870 units at $9.09), increasing direct ownership by 2% to 627,536 units (SEC Form 4)

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    10/9/25 9:01:51 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chen Bihua bought $3,524,297 worth of Class A Ordinary Shares (58,839 units at $59.90) (SEC Form 4)

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    10/10/23 4:00:43 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chen Bihua bought $16,800,343 worth of Class A Ordinary Shares (293,212 units at $57.30) (SEC Form 4)

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    10/4/23 5:52:22 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    Leadership Updates

    Live Leadership Updates

    View All

    ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

    Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo

    2/10/26 7:00:00 AM ET
    $IMA
    $MLTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MLTX
    Financials

    Live finance-specific insights

    View All

    MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

    Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to provide runway into the second half of 2027Reported results of its Phase 2 LEDA clinical trial in Palmoplantar Pustulosis (PPP) where sonelokimab (SLK) demonstrated clinically meaningful and statistically significant benefitReported an interim analysis of the long-term data from the VELA-1 and VELA-2 clinical trials in adults with Hidradenitis Suppurativa (HS), as well as an interim analysis of its VELA-TEEN clinical trial in adolescent HS, demonstrating the potential and competitive benefit of SL

    11/5/25 7:00:00 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

    Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026Other clinical trials of sonelokimab in palmoplantar pustulosis (PPP), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and adolescent HS progressing well and expected to support a catalyst-rich roadmap over the next 12 monthsEnded the second quarter with $425.1 million in cash, cash equivalents and short-term marketable debt securities with up to an additional $425 million in non-dilutive funds remaining accessible through previously announced debt-facility Z

    8/5/25 7:00:00 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

    MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab

    5/12/25 4:00:00 PM ET
    $HTGC
    $MLTX
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MLTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MoonLake Immunotherapeutics

    SC 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)

    11/12/24 10:32:13 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by MoonLake Immunotherapeutics

    SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)

    10/8/24 6:48:48 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by MoonLake Immunotherapeutics (Amendment)

    SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)

    3/5/24 4:59:16 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care